|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||11.11 - 11.87|
|52 Week Range||9.14 - 20.00|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||9.61|
|Earnings Date||Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.80|
MENLO PARK, Calif., Feb. 19, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2018 fourth quarter and full-year financial.
Glancy Prongay & Murray LLP announces an investigation on behalf of Corcept Therapeutics Incorporated investors concerning the Company and its officers’ possible violations of federal securities laws.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Law Offices of Howard G. Smith announces an investigation on behalf of Corcept Therapeutics Incorporated investors concerning the Company and its officers’ possible violations of federal securities laws.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Corcept Therapeutics Incorporated Read More...
NEW YORK , Feb. 5, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" ...
Corcept Therapeutics Incorporated (CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported preliminary fourth quarter revenue of $66.8 million, compared to $53.3 million in the fourth quarter of 2017. Preliminary 2018 revenue was $251.2 million, an increase of 58 percent from 2017. Corcept projects 2019 revenue of $285 - $315 million.
NEW YORK, Jan. 25, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQCM: CORT).
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
Biotech Corcept develops drugs to treat cortisol activity, such as Cushing's disease. The chief drug is Korlym, also known as mifepristone.
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome). The patent will expire in 2037. “This patent covers an important finding of our research – that with proper dose modulation, Korlym can safely be administered in combination with medications that are strong CYP3A inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.